With respect, I believe Mayo's projected range of $67-225B is for market cap not revenue.
Well, if so I've made an error. My numbers are not accurate.
The question then remains. What will be the potential range of annual revenues coming to Anavex when the company gets approval to sell blarcamesine to treat Alzheimer's in the US?
Please, everyone, post these projections. Of course, the Anavex naysayers will have easy posts. "Zero. The company can never get FDA approval." Others? How much can Anavex take in if and when they get FDA approval of blarcamesine for Alzheimer's in the US? Those of us with AVXL positions are interested to ponder the question.